# Everly Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/everly-health

- Industry: Medical Devices & Equipment
- Headquarters: Austin, US
- Website: www.everlyhealth.com
- Total disclosed funding: $245M
- Latest round: Series D (Nov 17, 2020)
- Investors on record: 14

## About

Everly Health, Inc. is a U.S.-based health technology company that specializes in providing at-home diagnostic testing solutions, facilitating accessible healthcare through innovative and user-friendly products.Everly Health, Inc. is focused on delivering diagnostic testing solutions that can be performed at home. Founded in 2015, the company is headquartered in Austin, Texas, US. Julia Cheek serves as the CEO and has a background in health technology innovation. Everly Health has completed 7 deals, with its latest funding round, Series E, occurring on March 23, 2021. The company has raised a total of USD 175.00 mn, with a current valuation of USD 2,373.29 mn.Everly Health provides a comprehensive suite of at-home diagnostic testing solutions designed to deliver modern, diagnostics-driven healthcare. Their primary offerings include over 30 different at-home tests that facilitate simple sample collection, with results and insights sent directly to users' devices within days. These tests address various health needs, including fertility and pregnancy essentials, crafted for sustainability with a net-zero plastic footprint. The company's products are utilized by a broad spectrum of clients, including national health plans, universities, and retail partners, effectively serving millions of end users across the United States. By leveraging their infrastructure and a national clinician network comprising hundreds of healthcare professionals, Everly Health creates a healthcare experience centered on accessibility and personalization, making their services available nationwide.Everly Health generates revenue through a multifaceted model combining B2B partnerships and direct-to-consumer sales. Clients, including major enterprise partners and retail brands, engage in structured transactions involving the provision of diagnostic tests to consumers. Enterprise clients may offer Everly Health's testing kits as part of health benefits, integrating these solutions into employee wellness programs. Additionally, the company’s direct-to-consumer sales allow individuals to purchase tests through their platform. While specific pricing plans and flagship products are not disclosed, the comprehensive nature of their service offerings positions Everly Health as a significant player in the telehealth and at-home diagnostic testing market. This business model supports their mission to improve healthcare access and outcomes for a diverse customer base.In March 2021, Everly Health raised USD 175.00 mn in Series E financing, which will be utilized to support the expansion of their at-home testing product lines and enhance the technological infrastructure of their services. The company is planning to launch new products aimed at addressing additional health needs and is targeting further expansion into new geographic markets throughout the United States in the near future.

## Funding rounds

- Series D, Nov 17, 2020, $175M — Highland Capital Partners, Greenspring Associates, 5Y Capital, Luxor Capital Group, BlackRock, Foresite Capital, TCG, Goodwater Capital, Next Coast Ventures, Portfolia
- Series C, Feb 20, 2020, $25M — Highland Capital Partners
- Series B, Feb 5, 2019, $30M — Highland Capital Partners, Goodwater Capital, Next Coast Ventures, SoGal Ventures, NextGen Venture Partners
- Series A, Dec 28, 2017, $13M — SoGal Ventures, NextGen Venture Partners, Full Tilt Capital
- Seed, Feb 17, 2016, $2.5M — Techammer, SoGal Ventures

## Investors

- Techammer — Seed
- SoGal Ventures (https://capitalatlas.ai/funds/sogal-ventures) — Seed, Series A, Series B
- NextGen Venture Partners (https://capitalatlas.ai/funds/nextgen-venture-partners) — Series A, Series B
- Full Tilt Capital (https://capitalatlas.ai/funds/full-tilt-capital) — Series A
- Highland Capital Partners (https://capitalatlas.ai/funds/highland-capital-partners) — Series B, Series C, Series D
- Goodwater Capital (https://capitalatlas.ai/funds/goodwater-capital) — Series B, Series D
- Next Coast Ventures (https://capitalatlas.ai/funds/next-coast-ventures) — Series B, Series D
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series D
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series D
- Luxor Capital Group (https://capitalatlas.ai/funds/luxor-capital-group) — Series D
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series D
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series D
- TCG (https://capitalatlas.ai/funds/tcg) — Series D
- Portfolia (https://capitalatlas.ai/funds/portfolia) — Series D